Plant Name: Senna alexandrina
Taxonomic Information:
Plant ID: NPO28260
Plant Latin Name: Senna alexandrina
Taxonomy Genus: Senna
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
72402
Plant-of-the-World-Online:
518323-1
Used in Medicines:
Country/Region:
India; Indonesia; JordanTraditional Medicine System:
Unani; Indian Folk; Homeopathy; Ayurveda; SiddhaGeographical Distribution:
Brazil; Mauritania; Sudan; Ethiopia; Somalia; Nigeria; Benin; Saudi Arabia; Algeria; Russia; Jordan; Dominican Republic; Iraq; Eritrea; Oman; Indonesia; United States; Mali; Yemen; Haiti; Pakistan; Chad; Mexico; Egypt; India; Uzbekistan; Djibouti; Colombia; Sri Lanka; Kenya; Niger; Tajikistan
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| MTNR1B; HTR7; MTNR1A; HTR1B; HTR1D; HTR2B; HTR2A; HTR1A; HTR2C; HTR6; | |
| TDP1; ALOX12; HSD17B2; HSD17B10; NOX4; ALOX15; ALDH1A1; POLB; | |
| PIM1; AXL; FLT3; CDK1; MAPK1; MET; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA14; CA7; CA4; | |
| PPARA; | |
| TYR; | |
| TP53; NFKB1; AHR; | |
| LMNA; FABP5; FABP4; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Small molecule receptor (family A GPCR) | MTNR1B | Melatonin receptor 1B | P49286 | CHEMBL1946 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | MTNR1A | Melatonin receptor 1A | P48039 | CHEMBL1945 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | Unclassified; | GO:0042310; vasoconstriction | 6.786E-11 | 1.231E-07 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR7 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.020E-10 | 2.825E-07 | CA12, CA14, CA2, CA4, CA7 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.137E-09 | 1.126E-06 | AHR, AXL, FLT3, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7, IGF1R, KDR, MET, MTNR1A, MTNR1B, NPSR1, PPARA, TSHR |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.391E-09 | 4.639E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.423E-08 | 8.376E-06 | AXL, FLT3, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7, IGF1R, KDR, MET, MTNR1A, MTNR1B, NPSR1, TSHR |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 5.391E-08 | 2.498E-05 | HTR1A, HTR1B, HTR7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.930E-08 | 3.144E-05 | CA12, CA14, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.782E-08 | 3.458E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 1.346E-07 | 5.528E-05 | HTR2A, HTR2B, HTR2C |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.786E-07 | 6.705E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0023052; signaling | GO:0007268; chemical synaptic transmission | 4.672E-07 | 1.419E-04 | HTR1B, HTR1D, HTR2A, HTR2C, HTR6, HTR7, MAPK1, MTNR1B |
| BP | GO:0007610; behavior | GO:0050795; regulation of behavior | 4.692E-07 | 1.419E-04 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 5.365E-07 | 1.537E-04 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR7 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 6.624E-07 | 1.803E-04 | CA2, CA7, HTR2A, HTR2B, HTR2C, KDR, NPSR1 |
| BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 9.237E-07 | 2.286E-04 | AHR, HTR7, MTNR1A, MTNR1B, PPARA, TP53 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 9.641E-07 | 2.359E-04 | ALOX12, CDK1, FLT3, HTR1A, HTR1B, HTR2A, HTR2B, IGF1R, KDR, MAPK1, PIM1, TSHR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.711E-06 | 3.882E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.384E-06 | 4.992E-04 | ALOX12, ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 3.190E-06 | 6.373E-04 | ALDH1A1, CYP1A1, CYP1B1, HSD17B2, HTR1A, HTR2A, HTR2C, MTNR1B, NFKB1 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 4.942E-06 | 9.120E-04 | ALOX12, AURKB, AXL, CDK1, HTR2B, IGF1R, KDR, LMNA, NFKB1, PIM1, TP53 |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 5.795E-06 | 9.632E-04 | HTR2A, HTR2C |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.795E-06 | 9.632E-04 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.795E-06 | 9.632E-04 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 5.795E-06 | 9.632E-04 | HTR2A, HTR2C |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 7.393E-06 | 1.142E-03 | AXL, CA2, CYP1A1, CYP1A2, FLT3, HSD17B2, HTR1B, NFKB1, TP53, TYR |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 7.906E-06 | 1.204E-03 | ALOX15, HTR2A, HTR2B, HTR2C, KDR, NOX4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.450E-05 | 2.024E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.736E-05 | 2.284E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.741E-05 | 2.284E-03 | CYP1A1, POLB, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0008502; melatonin receptor activity | 1.736E-05 | 2.284E-03 | MTNR1A, MTNR1B |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.736E-05 | 2.284E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.736E-05 | 2.284E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.311E-05 | 2.909E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.311E-05 | 2.909E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.466E-05 | 3.939E-03 | CYP1A1, CYP1A2 |
| BP | GO:0032501; multicellular organismal process | GO:0014827; intestine smooth muscle contraction | 3.466E-05 | 3.939E-03 | HTR1D, HTR2B |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.466E-05 | 3.939E-03 | CYP1A2, CYP2C9 |
| BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 4.133E-05 | 4.568E-03 | CDK1, FLT3, HTR2A, HTR2B, MAPK1, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 4.405E-05 | 4.772E-03 | HTR1B, IGF1R, MAPK1, NFKB1, NOX4, TP53, TSHR |
| BP | GO:0050896; response to stimulus | GO:0071502; cellular response to temperature stimulus | 5.768E-05 | 6.028E-03 | HTR1B, HTR2B |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 5.768E-05 | 6.028E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:2001023; regulation of response to drug | 6.456E-05 | 6.538E-03 | HTR1B, HTR2A, MET, TP53 |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 7.232E-05 | 7.191E-03 | ALOX15, CDK1, CYP1A1, PPARA, TP53 |
| BP | GO:0065007; biological regulation | GO:0030641; regulation of cellular pH | 8.328E-05 | 8.060E-03 | CA2, CA7, MAPK1, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.638E-05 | 8.208E-03 | CYP1A2, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 8.669E-05 | 8.208E-03 | AXL, FLT3, IGF1R, KDR, MET |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 8.932E-05 | 8.384E-03 | ALOX12, IGF1R, KDR, MAPK1, MET, NOX4, TP53 |
| MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 9.899E-05 | 9.144E-03 | AHR, PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.109E-04 | 9.866E-03 | AURKB, FLT3, IGF1R, KDR, PIM1 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.036E-16 | 1.128E-12 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR7 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 4.682E-16 | 1.699E-12 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 4.682E-16 | 1.699E-12 | HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C, HTR6, HTR7 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.303E-17 | 3.454E-15 | CYP2C9, HTR6, HTR7, HTR1D, ALOX15, HTR1A, HTR2B, HTR1B, HTR2C, MAPK1, ALOX12, HTR2A |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 3.304E-11 | 2.478E-09 | HTR6, MTNR1A, HTR7, MTNR1B, HTR1D, HTR1A, HTR2B, HTR1B, HTR2C, HTR2A, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.882E-08 | 7.057E-07 | HTR6, HTR1D, HTR1A, HTR1B, MAPK1, PPARA, NFKB1, TSHR |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.487E-10 | 1.744E-08 | CA12, CA2, CA4, CA7, CA14 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.950E-06 | 5.849E-05 | CDK1, HTR2B, HTR2C, MAPK1, HTR2A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.694E-06 | 1.424E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 9.650E-06 | 1.940E-04 | FLT3, PIM1, MAPK1, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.457E-05 | 2.428E-04 | HTR7, KDR, MAPK1, MET, NFKB1, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.035E-05 | 1.940E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 2.317E-05 | 2.897E-04 | MAPK1, TP53, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.841E-05 | 2.510E-04 | FLT3, MAPK1, TP53, MET |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.631E-05 | 2.447E-04 | CYP2C9, CYP1A2, ALDH1A1, CYP1A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.587E-05 | 2.985E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 6.307E-05 | 5.180E-04 | HTR6, HTR7, HTR2B, HTR2C, HTR2A |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.646E-05 | 5.180E-04 | MAPK1, TP53, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 6.562E-05 | 5.180E-04 | PIM1, CYP1B1, MAPK1, TP53, MET, NFKB1 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 8.225E-05 | 6.169E-04 | HTR2B, HTR2C, ALOX12, HTR2A |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.112E-04 | 7.597E-04 | KDR, MAPK1, TP53, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 4.093E-05 | 4.258E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.400E-04 | 8.752E-04 | KDR, MAPK1, TP53, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 6.307E-05 | 5.180E-04 | FLT3, TP53, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.165E-04 | 7.597E-04 | POLB, CDK1, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.179E-04 | 1.804E-03 | FLT3, MAPK1, MET, TP53, NFKB1, IGF1R |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.248E-04 | 1.804E-03 | LMNA, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.671E-04 | 1.603E-03 | MAPK1, PPARA, TP53, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 4.258E-05 | 4.258E-04 | CYP2C9, CYP1A2, ALOX15 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 4.797E-04 | 2.481E-03 | MAPK1, TP53, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.131E-04 | 7.597E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 5.017E-04 | 2.508E-03 | MAPK1, TP53, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.283E-03 | 5.498E-03 | KDR, MAPK1, MET, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 4.174E-04 | 2.236E-03 | CYP2C9, ALOX15, ALOX12 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 6.741E-04 | 3.160E-03 | MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.506E-03 | 5.792E-03 | KDR, MAPK1, MET, IGF1R |
| 09150 Organismal Systems | 09157 Sensory system | hsa04742 | Taste transduction | 9.796E-04 | 4.322E-03 | HTR1D, HTR1A, HTR1B |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.098E-03 | 7.185E-03 | CYP2C9, HSD17B2, CYP1A2, ALOX15, ALDH1A1, CYP1A1, ALOX12, TYR, HSD17B10 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.725E-03 | 6.311E-03 | PIM1, MAPK1, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 7.014E-04 | 3.188E-03 | MAPK1, MET, IGF1R |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.404E-03 | 5.690E-03 | TP53, NFKB1, IGF1R |
| 09150 Organismal Systems | 09159 Environmental adaptation | hsa04713 | Circadian entrainment | 1.447E-03 | 5.712E-03 | MTNR1A, MTNR1B, MAPK1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.582E-03 | 5.933E-03 | CDK1, MAPK1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 5.716E-04 | 2.766E-03 | FABP4, FABP5, PPARA |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.825E-03 | 6.517E-03 | MAPK1, NFKB1, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.818E-03 | 9.189E-03 | MAPK1, TP53, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 3.022E-03 | 9.643E-03 | CDK1, MAPK1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.818E-03 | 9.189E-03 | MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 2.108E-03 | 7.185E-03 | MAPK1, TP53 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.325E-03 | 5.521E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MTNR1B; HTR1D; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR2C; HTR6; |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; MTNR1A; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; MAPK1; TP53; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; HTR1A; HTR1B; HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; HTR1D; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; MTNR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; HTR1A; HTR1B; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| NA: NA | HIV infections | NA | AHR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR2C; HTR6; MTNR1A; HTR1A; HTR1B; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2B; HTR2C; HTR1A; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; HTR2C; HTR1A; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Circadian rhythm sleep disorder | G47.2 | MTNR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR6; HTR1A; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; HTR1A; |
| NA: NA | Addiction | NA | HTR2A; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| NA: NA | Edema | NA | CA2; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR6; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; HTR1B; HTR1D; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HTR2A; HTR2C; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; HTR1A; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | HTR2A; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| NA: NA | Episode | NA | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; HTR2C; MTNR1A; HTR1A; HTR1B; HTR1D; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| NA: NA | Primary insomnia | NA | HTR2C; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; MAPK1; TP53; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| NA: NA | Social phobia | NA | HTR1A; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR2A; HTR2B; HTR1A; HTR1D; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; TP53; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; HTR2C; HTR6; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; TP53; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; HTR2A; HTR2C; HTR6; HTR1A; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HTR1A; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
